Advances in culturing hepatitis C virus have given hope for a universal cell culture system amenable to primary isolate replication. However, low replication efficiency needs to be overcome. The development of fully susceptible yet immunocompetent in vivo models would aid research towards a prophylactic vaccine.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout

References
Hill, A. & Cooke, G. Science 345, 141–142 (2014).
Lohmann, V. & Bartenschlager, R. J. Med. Chem. 57, 1627–1642 (2014).
Wakita, T. et al. Nature Med. 11, 791–796 (2005).
Blight, K. J., McKeating, J. A. & Rice, C. M. J. Virol. 76, 13001–13014 (2002).
Saeed, M. et al. Nature 524, 471–475 (2015).
Yamane, D. et al. Nature Med. 20, 927–935 (2014).
Vercauteren, K., de Jong, Y. P. & Meuleman, P. Curr. Opin. Virol. 13, 67–74 (2015).
Bukh, J. et al. J. Viral Hepat. 8, 228–231 (2001).
Sourisseau, M. et al. Gastroenterology 145, 966–969 (2013).
Scull, M. A. et al. Hepatology 62, 57–67 (2015).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Paul, D., Bartenschlager, R. Hepatitis C virus's next top models?. Nat Microbiol 1, 15018 (2016). https://doi.org/10.1038/nmicrobiol.2015.18
Published:
DOI: https://doi.org/10.1038/nmicrobiol.2015.18